Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4–6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiuli, Tong, Dali, Liu, Gaolei, Xu, Jing, Do, Khang, Geary, Kyla, Zhang, Dianzheng, Zhang, Jun, Zhang, Yao, Li, Yaoming, Bi, Gang, Lan, Weihua, Jiang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596596/
https://www.ncbi.nlm.nih.gov/pubmed/28837141
http://dx.doi.org/10.1038/cddis.2017.417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596596/
https://www.ncbi.nlm.nih.gov/pubmed/28837141
http://dx.doi.org/10.1038/cddis.2017.417

Ejemplares similares